GlassScriptPhysician profile
Bruce Gordon Houston
NPI 1285629907
$19,121.82
in general payments reported to CMS, 2019-2025
54 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,234 · 2020: $2,120 · 2021: $3,124 · 2022: $2,890 · 2023: $2,861 · 2024: $2,603 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,706 · Education: $48.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,706.06 |
| Education | $48.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,494.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,574.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,381.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,143.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $941.06 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $930.81 | 2022-2025 | |
| Amgen INC. | $834.62 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $766.65 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $743.74 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $694.38 | 2019-2025 | Ofev, Jardiance |
| Dexcom, INC. | $622.71 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $593.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $574.69 | 2019-2024 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $432.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $424.42 | 2019-2025 | Eliquis, Camzyos |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $388.42 | 2019-2020 | |
| Organogenesis INC. | $346.85 | 2021-2025 | Puraply, Puraply Wound Matrix |
| Neurocrine Biosciences, INC. | $333.22 | 2022-2024 | Ingrezza, Ongentys |
| Sumitomo Pharma America, INC. | $294.29 | 2023-2025 | Gemtesa, Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $261.43 | 2019-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $251.58 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $250.53 | 2019-2022 | |
| Esperion Therapeutics, INC. | $205.28 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $202.02 | 2022 | |
| Corcept Therapeutics | $194.93 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $190.49 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $177.57 | 2019-2022 | |
| Abbott Laboratories | $171.25 | 2021-2024 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $151.01 | 2020-2023 | Linzess |
| Otsuka America Pharmaceutical, INC. | $139.62 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.82 | 2019-2024 | Xifaxan |
| Eisai INC. | $111.55 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $107.62 | 2019-2022 | |
| Boston Scientific Corporation | $95.10 | 2022 | |
| Shield Therapeutics INC | $83.53 | 2023-2025 | Accrufer |
| Phathom Pharmaceuticals, INC. | $81.39 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $77.78 | 2025 | Ibsrela |
| Teleflex LLC | $77.38 | 2024 | Urolift |
| Daiichi Sankyo INC. | $76.22 | 2022-2023 | Injectafer |
| Biogen, INC. | $65.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $62.55 | 2020-2021 | |
| Amarin Pharma, INC. | $62.20 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $53.38 | 2021 | |
| Kvk-Tech, INC. | $50.56 | 2019 | |
| Paratek Pharmaceuticals, INC. | $39.76 | 2023 | Nuzyra |
| Ucb, INC. | $38.29 | 2024 | Nayzilam |
| Nevro Corp. | $34.70 | 2021 | |
| Corium, LLC | $33.25 | 2023 | Adlarity |
| Sanofi Pasteur INC. | $28.68 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $27.71 | 2021 | |
| Genentech USA, INC. | $26.58 | 2019-2025 | Ocrevus Zunovo |
| Exact Sciences Corporation | $19.36 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $18.91 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Scilex Pharmaceuticals INC. | $13.00 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Houston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.